Symptom assessment tools for gastroesophageal reflux disease (GERD) treatment

Relief of symptoms, both typical and atypical, is the mainstay of therapy for patients with gastroesophageal reflux disease (GERD); however, evaluation of GERD symptoms' response to treatment has been hampered by the lack of a questionnaire that meets all the criteria of an ideal evaluative GERD symptom assessment tool. These criteria are: sensitivity in GERD patients, covering all symptom dimensions (multidimensional construct), assessment of frequency and intensity of "typical" and "atypical" GERD symptoms, practical and economical, easy to understand, responsive over short time intervals, use as a patient self-assessment tool, amenable to daily use, psychometrically validated, and translation into many languages with cross-cultural adaptation. Thus far, 14 instruments have been developed to assess GERD symptoms and potentially can be used to evaluate treatment response during a therapeutic trial in GERD patients. However, comparison of the different evaluative tools is needed.     

Epidemiological study on the incidence of gastroesophageal reflux disease symptoms in patients in acute treatment with NSAIDs

Gastroesophageal reflux disease (GERD) is one of the most common disorders in medical practice. The prevalence of GERD in Spain has been reported to be 15%. GERD is associated with esophageal and extra-esophageal complications and with a negative impact on the patients’ related quality of life. Several risk factors have been related with the development of GERD, including smoking, coffee intake, alcohol consumption and use of medication, such as NSAIDs. If untreated, GERD symptoms can lead to a decrease of patients’ related quality of life and to treatment discontinuation. From this study, it was confirmed that the relationship between GERD and some behavioral risk factors, such as alcohol intake, smoking and coffee consumption, and concomitant treatment with NSAID drugs. Among the protective factors for GERD, antisecretory agents and antacids have shown to be essential for the control of GERD, the use of proton pump inhibitors being the predominant protective factor.     

Endoluminal Therapy for Gastroesophageal Reflux Disease: In Between the Pill and the Knife?

Gastroesophageal reflux disease (GERD) is a chronic disease characterized by symptoms of heartburn and acid regurgitation. Uncontrolled GERD can significantly impact quality of life, can lead to complications, and increases the risk of esophageal cancer. Over the past few decades, there has been an increasing prevalence of GERD among adults in Western populations. The use of proton pump inhibitors (PPI) in conjunction with lifestyle modifications remains the mainstay therapy. However, the efficacy of this intervention is often hampered by adherence, costs, and the risks of long-term PPI use. Anti-reflux surgery is an option for patients with refractory symptoms or in those in whom medical therapy is contraindicated or not desirable. While conventional surgery has an acceptable safety profile, there has been an increasing interest in alternate treatments that may potentially offer similar results and be associated with a faster recovery. Recent advances in interventional endoluminal techniques have introduced novel incisionless anti-reflux procedures. While the current data are promising, further larger prospective studies are needed in order to assess the long-term efficacy of endoluminal therapies and its place among the treatment options for GERD.     

Refractory GERD: What is it?

Refractory gastroesophageal reflux disease (GERD) is very common and may affect up to 40% of patients who use a proton pump inhibitor (PPI) once daily. Refractory GERD can present as incomplete or lack of response to PPI therapy. The disorder is clearly driven by patients, who present with a wide range of symptom severity and frequency while on PPI treatment. Poor compliance and improper timing of PPI consumption should always be excluded before further evaluation of this patient population. The putative mechanisms for refractory GERD include weakly acidic reflux, duodenogastroesophageal/bile reflux, visceral hypersensitivity, delayed gastric emptying, psychological comorbidity, and concomitant functional bowel disorders. Reduced PPI bioavailability, rapid PPI metabolism, PPI resistance, nocturnal reflux, and Helicobacter pylori infection status have very limited roles in refractory GERD. The contribution of eosinophilic esophagitis to refractory GERD is still unknown. Pill-induced esophagitis, Zollinger-Ellison syndrome, achalasia, and other disorders are rarely responsible for PPI failure and usually are not confused with GERD.     

Gastroesophageal reflux disease in intellectually disabled individuals: how often, how serious, how manageable?

Gastroesophageal reflux disease (GERD) is an important and frequently occurring problem among intellectually disabled individuals (IDI). Early suspicion and recognition of the presence of GERD in IDI is the cornerstone of adequate management of these patients. The prevalence of GERD among institutionalized IDI with an IQ < 50 is about 50%, with 70% of these reflux patients having endoscopically established reflux esophagitis. In case of symptoms as hematemesis, rumination, or dental erosions, there is an increased risk for GERD. GERD has also been shown to be associated with cerebral palsy, an IQ < 35, scoliosis, and the use of anticonvulsant drugs or benzodiazepines. To establish the diagnosis, 24-h pH measurement or endoscopy should be used in all those intellectually disabled individuals in whom GERD clinically is suspected. The efficacy of proton-pump inhibitors (PPIs) in IDI with GERD is indisputable. In IDI, adults as well as children, PPIs are highly effective, independent of the severity of esophagitis. Marked improvement of symptoms and quality of life can be noticed after medical treatment, thereby decreasing the need for surgery in this complicated group of patients.     

The association of gastroesophageal reflux disease with asthma and chronic cough in the adult

Gastroesophageal reflux disease (GERD) is a common condition which is particularly prevalent in patients with asthma and chronic cough. Physiologic changes caused by asthma and chronic cough promote acid reflux. GERD is also considered by many investigators as a factor contributing to airway inflammation. An etiological relationship between GERD and asthma/chronic cough and vice versa has been supported by a large number of experimental and clinical findings and refuted by others. Although further controlled studies are needed to clarify this relationship, GERD and asthma/chronic cough appear to be linked to each other. The association of GERD with asthma and chronic cough involves nerve reflexes, cytokines, inflammatory and neuroendocrine cells and, in some patients, tracheal aspiration of refluxing gastric fluids. GERD may present with typical symptoms but can also be asymptomatic. Sensitive methods for diagnosing GERD are available, which include esophageal pH monitoring, acid provocative tests, modified barium swallow and endoscopy. Consideration of the association of GERD with asthma and chronic cough is of practical value in the management of chronic cough or asthma resistant to treatment. Treatment of GERD in patients with asthma has been consistently shown to improve respiratory symptoms but not necessarily pulmonary function tests. Surgical treatment can be a useful and cost-effective approach in selected patients with asthma and GERD.     

Gastroesophageal reflux disease--state of the art

Gastroesophageal reflux disease (GERD) is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus; heartburn, its most common manifestation, occurs in 7% to 10% of the U.S. population on a daily basis. In addition, many so-called extraesophageal or atypical symptoms, including chronic cough, laryngitis and other otolaryngologic conditions, asthma, and unexplained chest pain, can be associated with GERD, but these patients appear to have a decreased frequency of heartburn, making the diagnosis of GERD difficult. All patients can be successfully managed with appropriate, titrated use of pharmacologic therapy. Antireflux surgery should thus be considered as an option only for patients who cannot afford or choose not to continue long-term medical therapy and for the rare patient with side effects or resistance to proton pump inhibitors. Endoscopic therapy for reflex should be considered as an experimental technology needing continuing evaluation.     

LINX™ Reflux Management System: magnetic sphincter augmentation in the treatment of gastroesophageal reflux disease

Gastroesophageal reflux disease (GERD), commonly manifested by heartburn or regurgitation, is a chronic, progressive condition in which failed sphincter function allows the contents of the stomach to reflux into the esophagus, the airways and the mouth. Chronic GERD affects 10% of Western society. The majority of patients receive adequate relief from proton pump inhibitors, but up to 40% have incomplete relief of symptoms that cannot be addressed by increasing the dose of medications. The laparoscopic Nissen fundoplication is the surgical gold standard; however, the level of technical difficulty and its side effects have limited its use to less than 1% of the GERD population. These factors have contributed to the propensity of patients to persist with medical therapy, even when inadequate to control symptoms and complications of the disease. Consequently, a significant gap in the treatment continuum for GERD remains evident in current clinical practice. The LINX^? Reflux Management System (Torax Medical) is designed to provide a permanent solution to GERD by augmenting the physiologic function of the sphincter barrier with a simple and reproducible laparoscopic procedure that does not alter gastric anatomy and can be easily reversed if necessary.     

Is there a relationship between obstructive sleep apnea and gastroesophageal reflux disease?

BACKGROUND AND AIMS: The causative relationship between obstructive sleep apnea (OSA) and gastroesophageal reflux disease (GERD) remains an area of controversy. The aim of the study is to further explore the relationship between OSA and GERD in a large group of patients with OSA. METHODS: One hundred thirty-six patients referred for polysomnographic studies at the University of Arizona Sleep Center were included in this study. All patients were assessed by means of a demographic survey, the validated GERD Symptom Checklist, and the Sleep Heart Health Study Sleep Habits Questionnaire. Polysomnograms were scored for objective measures of sleep and breathing. OSA is defined as an apnea-hypopnea index > 5 with compatible symptoms. RESULTS: Of the 136 subjects, 101 (74%) were found to have OSA. Self-report of heartburn or acid regurgitation symptoms was unrelated to severity of sleep apnea. Additionally, OSA was not influenced by the severity of GERD. Objective measures of disordered sleep had stronger associations with age, smoking, and alcohol use than GERD in men and stronger associations with age and body mass index than GERD in women. Subjectively reported sleep quality was affected more strongly by GERD severity than by age, smoking, alcohol use, or the presence of OSA. Only females administered antireflux medications were less likely to report poor sleep quality. CONCLUSIONS: Subjective reports of sleep quality were affected by GERD severity, but an objective correlation between OSA and GERD was lacking. This may suggest that GERD and OSA are common entities that share similar risk factors, but appear not to be causally linked.     

Gastroesophageal reflux disease. Heart-burn from a psychological view

Although gastroesophageal reflux disease (GERD) can be traced back to disorders of the gastroesophageal junction, stress and other relevant psychological factors can play an important role in the process of GERD. It would seem that, primarily, altered symptom perception based on threshold reduction exists in some patients. In an effort to describe the sensitisation for reflux symptoms, both central and peripheral factors can be discussed. The following is conceivable: that well defined personality factors moderate the effect of stress on the gastroesophageal junction, just as they can influence the perception and assessment of symptoms. Additionally, psychiatric disorders as comorbidities can also accompany GERD. For this reason, it is necessary to consider if an extension of hitherto psychological interventions could be helpful in patients with a subjective link between reflux and stress on an emotional personality related level, or in patients with attendant psychiatric disorders. This broadening relates both to the conservative use of antireflux medication and to surgical therapy, since a postoperative shift in symptoms can occur. The effectiveness of psychological interventions in several gastrointestinal patient groups could already be shown in the past, whereas evidence for their effectiveness in patients suffering with GERD is partly still outstanding and should be investigated in the future especially as several individual promising starts have been made.     

Usage of Supplemental Alternative Medicine by Community-Based Patients with Gastroesophageal Reflux Disease (GERD)

There is an increasing trend towards alternative medicine usage by the general US population. However, the extent and type of supplemental alternative medicine used specifically by community-based patients with GERD is unknown. A previously validated questionnaire that included questions about patient demographics, 18 types of alternative medicine, and attitudes towards alternative and conventional medicine was utilized. Consecutive patients seen by community-based physicians in Arizona (Tucson, Phoenix, and Flagstaff) and Wisconsin (Milwaukee) for GERD received the questionnaire during the years 1999 and 2000. Patients completed the questionnaire and returned it to the Tucson VA Medical Center by mail. A total of 185 patients were surveyed (82 men, mean age 55.8 years). Of those, 61.6% used alternative medicine for any reason. However, only 3.8% of patients used supplemental alternative medicine for GERD. Females were twice as likely (95% CI, 1.10–3.67) to use alternative medicines for any reason (including GERD). Patients with daily acid regurgitation were 5.75 times (95% CI, 1.03–32.17) more likely than patients with less frequent acid regurgitation to use alternative medicines specifically for GERD. None of the other demographics, health characteristics, or attitudes were predictive of supplemental alternative medicine use for any reason (or specifically for GERD). In conclusion, only a small percentage of GERD patients seen by community-based practitioners use supplemental alternative medicine specifically for GERD symptoms, despite a higher usage of supplemental alternative medicine for non-GERD-related illness. Being female and having acid regurgitation daily were positively associated with alternative medicine usage for GERD.     

胃食管反流病大鼠模型探讨

胃食管反流病GERD为消化科常见病之一,其发病机制复杂。大鼠模型可用来研究GERD的发病机制并为新的临床治疗方式带来希望。目前国内外有两类方法构建GERD大鼠模型,一类是外源性食管灌注化学物质诱发,另一类是手术干预改变大鼠胃肠道生理结构来实现。本综述主要从急性GERD大鼠模型和慢性GERD大鼠模型两大方面探讨。     

酸敏感受体与心理因素在胃食管反流病内脏高敏感产生的作用研究

胃食管反流病（GERD）是一类常见的消化道良性疾病,通常以烧心和反酸为典型症状出现。临床上以质子泵抑制剂做为首选药物控制GERD患者的症状,但部分患者治疗效果并不理想。目前认为,食管内脏高敏感（VH）是GERD关键的发病机制之一,成为了近年来的研究热点。VH表现为低阈值刺激即可引起的相对强烈的反应或不适,本文从酸敏感受体和心理因素的角度对GERD内脏高敏感产生中的作用做一综述。     

2型糖尿病与胃食管反流病的相关性研究进展

2型糖尿病（T2DM）是目前发病率较高的代谢相关疾病,胃食管反流病（GERD）是发病率较高的消化道疾病之一,GERD被认为是T2DM并发症中慢性胃肠道疾病之一。T2DM和GERD的发生发展机制目前尚未研究明确,T2DM并发GERD患者影响食管动力学功能可能与胰岛素抵抗、高血糖、自主神经病变、胃肠激素、一过性下食管括约肌松弛及糖尿病药物使用有关,本文主要以T2DM与GERD相关性研究进展作以总结叙述。     

炎症因子及氧化应激在GERD食管黏膜炎症损伤发生中的作用

我国胃食管反流病（GERD）发病率一直呈上升趋势。GERD病因较多,发病的机制复杂,发病机制尚未清楚。抑酸治疗是治理GERD的最佳途径,质子泵抑制剂被用于GERD的常规治疗,但仍有一部分的患者对其疗效欠佳。近年来,炎症因子（ICs）和氧化应激（OS）在食管黏膜损伤中的作用逐渐受到重视。ICs及OS为靶向的新型药物治疗,对抑酸药物疗效欠佳的GERD患者带来希望,也为其诊断和治疗开辟新的途径,本文对以上方面研究现状作一综述。     

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

Guidelines for the diagnosis and treatment of gastroesophageal reflux disease (GERD) were published in 1995 and updated in 1999. These and other guidelines undergo periodic review. Advances continue to be made in the area of GERD, leading us to review and revise previous guideline statements. GERD is defined as symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus. These guidelines were developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee, and approved by the Board of Trustees. Diagnostic guidelines address empiric therapy and the use of endoscopy, ambulatory reflux monitoring, and esophageal manometry in GERD. Treatment guidelines address the role of lifestyle changes, patient directed (OTC) therapy, acid suppression, promotility therapy, maintenance therapy, antireflux surgery, and endoscopic therapy in GERD. Finally, there is a discussion of the rare patient with refractory GERD and a list of areas in need of additional study.     

Gastroesophageal reflux disease and irritable bowel syndrome: A common overlap syndrome

Gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS) are very common disorders in the general population. Symptoms of IBS are commonly encountered in GERD patients, and symptoms of GERD are not uncommon in IBS patients. GERD patients consistently report lower abdominal symptoms, which may be part of the spectrum of GERD symptoms. Alternatively, GERD and IBS may be two distinct manifestations of a similar underlying pathophysiologic process that can affect different levels of the gastrointestinal tract. Although the reason for the overlap observed between GERD and IBS remains to be elucidated, recent studies have demonstrated that GERD patients who also suffer from IBS-like symptoms perceive their GERD-related symptoms as more severe and are less likely to respond to antireflux treatment, as compared with those without IBS.     

Clinical implications of gastroesophageal reflux disease and swallowing dysfunction in COPD

The intimate anatomical and physiologic relationship between the upper airway and esophagus consists of complex interactions between various muscles and nerves with both voluntary and involuntary patterns of control. Alterations in this harmonic relationship can lead to swallowing abnormalities ranging from dysphagia to gross aspiration, gastroesophageal reflux disease (GERD) and chronic cough. There is a paucity of data regarding pathologic alterations in the upper airway-esophageal relationship in patients with COPD. The association between GERD and respiratory symptoms is well recognized in the setting of asthma; however, the nature of this relationship remains controversial. The association of GERD and COPD is even less clear. A review of the limited data on GERD and swallowing abnormalities in patients with COPD indicate that prevalence of GERD and esophageal disorders in patients with COPD is higher than in the normal population. However, its contribution to respiratory symptoms, bronchodilator use and pulmonary function in patients with COPD remains unknown. Although dysphagia and swallowing dysfunction on videofluoroscopic swallow evaluation are common in patients with COPD, their role as exacerbators of COPD remains to be elucidated. Further clinical research is necessary to evaluate the role of GERD and swallowing dysfunction in both stable and acute exacerbation of COPD.     

胃食管反流病的危险因素以及相关疾病的研究概况

胃食管反流病（GERD）是西方国家比较常见的疾病,近年亚洲国家的发病率呈上升趋势,其发病机制复杂。与GERD发生相关的分子机制主要包括IL-1β、IL-8、E-钙黏蛋白、PAR-2、COL3A1等,遗传因素、肥胖、生活方式、精神心理因素、药物、人口因素、食管裂孔疝等可能是GERD的危险因素。此外,GERD可导致多种食管外相关疾病和食管腺癌。本文就此作一综述。